Truist Securities Downgrades Evolent Health to Hold, Maintains Price Target to $7
Truist Securities analyst Jailendra Singh downgrades Evolent Health (NYSE: EVH ) from Buy to Hold and maintains the price target from $7 to $7.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.